Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.
benzinga_article
Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.
